Please use this identifier to cite or link to this item: https://doi.org/10.1158/1535-7163.MCT-11-0044
Title: Pharmacodynamic evaluation of the target efficacy of SB939, an oral HDAC inhibitor with selectivity for tumor tissue
Authors: Novotny-Diermayr, V.
Sausgruber, N.
Loh, Y.K.
Pasha, M.K.
Jayaraman, R.
Hentze, H.
Yong, W.-P. 
Goh, B.-C.
Toh, H.-C.
Ethirajulu, K.
Zhu, J.
Wood, J.M.
Issue Date: Jul-2011
Citation: Novotny-Diermayr, V., Sausgruber, N., Loh, Y.K., Pasha, M.K., Jayaraman, R., Hentze, H., Yong, W.-P., Goh, B.-C., Toh, H.-C., Ethirajulu, K., Zhu, J., Wood, J.M. (2011-07). Pharmacodynamic evaluation of the target efficacy of SB939, an oral HDAC inhibitor with selectivity for tumor tissue. Molecular Cancer Therapeutics 10 (7) : 1207-1217. ScholarBank@NUS Repository. https://doi.org/10.1158/1535-7163.MCT-11-0044
Abstract: SB939 is an oral histone deacetylase (HDAC) inhibitor currently in phase II clinical trials potently inhibiting class I, II, and IV HDACs with favorable pharmacokinetic properties, resulting in tumor tissue accumulation. To show target efficacy, a Western blot assay measuring histone H3 acetylation (acH3) relative to a loading control was developed, validated on cancer cell lines, peripheral blood mononuclear cells (PBMC), and in animal tumor models. Exposure of cells to 60 nmol/L (22 ng/mL) SB939 for 24 hours was sufficient to detect an acH3 signal in 25 μg of protein lysate. AcH3 levels of liver, spleen, PBMCs, bone marrow and tumor were measured in BALB/c mice, HCT-116 xenografted BALB/c nude mice, or in SCID mice orthotopically engrafted with AML (HL-60) after oral treatment with SB939. AcH3 could only be detected after treatment. In all tissues, the highest signal detected was at the 3-hour time point on day 1. On day 15, the signal decreased in normal tissues but increased in cancerous tissues and became detectable in the bone marrow of leukemic mice. In all tissues, acH3 correlated with SB939 dose levels (r2 = 0.76-0.94). When applied to PBMCs from 30 patients with advanced solid malignancies in a phase I clinical trial, a dose-dependent (10-80 mg) increase in relative acH3 was observed 3-hour postdose on day 1, correlating with Cmax and AUC of SB939 concentrations in plasma (r = 0.97, P = 0.014). Our data show that the favorable pharmacokinetic and pharmacodynamic properties of SB939 are translated from preclinical models to patients. ©2011 AACR.
Source Title: Molecular Cancer Therapeutics
URI: http://scholarbank.nus.edu.sg/handle/10635/110765
ISSN: 15357163
DOI: 10.1158/1535-7163.MCT-11-0044
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

22
checked on Jan 27, 2023

WEB OF SCIENCETM
Citations

19
checked on Jan 18, 2023

Page view(s)

212
checked on Jan 26, 2023

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.